Lv1
10 积分 2026-03-10 加入
Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial
23天前
已完结
Dual-tracer PET in prostate synovial sarcoma: discordant FDG and PSMA uptake with metastatic patterns
25天前
已完结
Dual-tracer PET in prostate synovial sarcoma: discordant FDG and PSMA uptake with metastatic patterns
25天前
已完结
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial
28天前
已完结
皖公网安备34019202002308
